These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31168012)

  • 1. [Hodgkin lymphoma].
    Nishikori M
    Rinsho Ketsueki; 2019; 60(5):447-452. PubMed ID: 31168012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
    Rinaldi I
    Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in relapsed classical hodgkin lymphoma.
    Dinner S; Advani R
    J Natl Compr Canc Netw; 2013 Aug; 11(8):968-76. PubMed ID: 23946175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hodgkin's lymphoma and CD30 signal transduction.
    Horie R; Higashihara M; Watanabe T
    Int J Hematol; 2003 Jan; 77(1):37-47. PubMed ID: 12568298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma.
    Hartmann S; Goncharova O; Portyanko A; Sabattini E; Meinel J; Küppers R; Agostinelli C; Pileri SA; Hansmann ML
    Mod Pathol; 2019 Jan; 32(1):37-47. PubMed ID: 30140037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
    Gruss H-J ; Herrmann F
    Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphomagenesis in Hodgkin lymphoma.
    Matsuki E; Younes A
    Semin Cancer Biol; 2015 Oct; 34():14-21. PubMed ID: 25725205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts.
    Nonaka M; Horie R; Itoh K; Watanabe T; Yamamoto N; Yamaoka S
    Oncogene; 2005 Jun; 24(24):3976-86. PubMed ID: 15782119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells.
    Horie R; Watanabe T; Morishita Y; Ito K; Ishida T; Kanegae Y; Saito I; Higashihara M; Mori S; Kadin ME; Watanabe T
    Oncogene; 2002 Apr; 21(16):2493-503. PubMed ID: 11971184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells.
    Watanabe M; Ogawa Y; Ito K; Higashihara M; Kadin ME; Abraham LJ; Watanabe T; Horie R
    Am J Pathol; 2003 Aug; 163(2):633-41. PubMed ID: 12875982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells.
    Schwarzer R; Dörken B; Jundt F
    Leukemia; 2012 Apr; 26(4):806-13. PubMed ID: 21946908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
    Carlo-Stella C; Santoro A
    Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
    Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
    Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
    Cao H; Yamamoto K; Yang LX; Weber R
    Anticancer Res; 2013 Sep; 33(9):3879-85. PubMed ID: 24023323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.
    Hansen HP; Engels HM; Dams M; Paes Leme AF; Pauletti BA; Simhadri VL; Dürkop H; Reiners KS; Barnert S; Engert A; Schubert R; Quondamatteo F; Hallek M; Pogge von Strandmann E
    J Pathol; 2014 Mar; 232(4):405-14. PubMed ID: 24659185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
    Younes A; Ansell SM
    Semin Hematol; 2016 Jul; 53(3):186-9. PubMed ID: 27496310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment strategy for pediatric Hodgkin lymphoma].
    Koga Y
    Rinsho Ketsueki; 2022; 63(9):1316-1324. PubMed ID: 36198558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Liu WR; Shipp MA
    Blood; 2017 Nov; 130(21):2265-2270. PubMed ID: 29167175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
    Szydłowski M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Derezińska E; Hoser G; Wasilewska D; Szymańska-Giemza O; Jabłońska E; Białopiotrowicz E; Sewastianik T; Polak A; Czardybon W; Gałęzowski M; Windak R; Zaucha JM; Warzocha K; Brzózka K; Juszczyński P
    Blood; 2017 Sep; 130(12):1418-1429. PubMed ID: 28698206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.